Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 14.78
+0.04 (0.27%)
Feb 3, 2026, 1:04 PM CST
SHA:600535 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 1,098 | 955.59 | 1,071 | -264.24 | 2,359 | 1,126 |
Depreciation & Amortization | 484.02 | 484.02 | 504.91 | 517.95 | 487.77 | 539.67 |
Other Amortization | 18.48 | 18.48 | 11.23 | 14.73 | 15.23 | 50.36 |
Loss (Gain) From Sale of Assets | -2.11 | -2.11 | -0.15 | -1.48 | -44.22 | -1.73 |
Asset Writedown & Restructuring Costs | 218.01 | 218.01 | 1.78 | 352.26 | 265.48 | 66.41 |
Loss (Gain) From Sale of Investments | 198.5 | 198.5 | 270.75 | 1,158 | -1,682 | -355.07 |
Provision & Write-off of Bad Debts | 0.62 | 0.62 | 8.19 | -1.34 | -5.35 | 65.46 |
Other Operating Activities | -533.27 | -73.79 | -2.03 | -31.24 | 123.82 | 254.5 |
Change in Accounts Receivable | 78.22 | 78.22 | 1,243 | 535.51 | 1,231 | -397.93 |
Change in Inventory | 18.32 | 18.32 | -220.72 | -2.86 | -198.37 | 56.58 |
Change in Accounts Payable | 121.58 | 121.58 | -395.35 | 36.56 | 243.78 | 324.51 |
Change in Other Net Operating Assets | - | - | 67.76 | 11.01 | 3.44 | 15.17 |
Operating Cash Flow | 1,697 | 2,015 | 2,576 | 2,280 | 2,801 | 1,791 |
Operating Cash Flow Growth | -36.58% | -21.78% | 12.98% | -18.62% | 56.39% | 6.61% |
Capital Expenditures | -461.15 | -564.94 | -668.82 | -404.41 | -571.73 | -408.81 |
Sale of Property, Plant & Equipment | 23.8 | 27.58 | 1.19 | 1.34 | 68.92 | 6.3 |
Cash Acquisitions | - | - | - | - | -147.31 | - |
Divestitures | 83.38 | - | - | - | 424.19 | 734.01 |
Investment in Securities | 855.93 | -287.57 | -134.14 | -919.91 | 126.42 | 39.33 |
Other Investing Activities | 197.09 | -115.99 | -1,307 | 56.75 | 56.76 | 89.9 |
Investing Cash Flow | 699.11 | -940.87 | -2,109 | -1,266 | -42.83 | 865.86 |
Short-Term Debt Issued | - | 1,052 | 213.91 | 102.79 | 1 | 57.3 |
Long-Term Debt Issued | - | 1,451 | 1,817 | 2,711 | 1,441 | 4,937 |
Total Debt Issued | 1,467 | 2,504 | 2,031 | 2,814 | 1,442 | 4,994 |
Short-Term Debt Repaid | - | -1,132 | -127 | -9.87 | -82.14 | -82.72 |
Long-Term Debt Repaid | - | -2,597 | -1,345 | -2,311 | -2,717 | -6,308 |
Total Debt Repaid | -3,554 | -3,729 | -1,472 | -2,321 | -2,799 | -6,391 |
Net Debt Issued (Repaid) | -2,087 | -1,225 | 559.55 | 492.71 | -1,358 | -1,397 |
Repurchase of Common Stock | - | - | - | -60.8 | -56.43 | -94.76 |
Common Dividends Paid | -831.76 | -1,042 | -563.22 | -553.97 | -610.49 | -799.29 |
Other Financing Activities | 688.42 | -186.05 | -1,193 | -114.58 | -458.73 | -20.12 |
Financing Cash Flow | -2,231 | -2,454 | -1,196 | -236.63 | -2,483 | -2,311 |
Foreign Exchange Rate Adjustments | -3.23 | 0.16 | -1.26 | 30.39 | 1.94 | -12.15 |
Net Cash Flow | 162.45 | -1,380 | -730.54 | 807.36 | 276.97 | 334.16 |
Free Cash Flow | 1,236 | 1,450 | 1,907 | 1,875 | 2,229 | 1,382 |
Free Cash Flow Growth | -39.21% | -23.98% | 1.68% | -15.89% | 61.28% | 45.61% |
Free Cash Flow Margin | 14.81% | 17.06% | 21.98% | 21.71% | 28.04% | 10.18% |
Free Cash Flow Per Share | 0.83 | 0.97 | 1.28 | 1.28 | 1.48 | 0.92 |
Cash Interest Paid | 8.41 | 8.41 | - | 4.05 | - | 0.2 |
Cash Income Tax Paid | 1,057 | 993.38 | 1,099 | 1,106 | 1,008 | 1,112 |
Levered Free Cash Flow | 529.01 | 956.26 | 1,348 | 1,517 | 2,531 | 5,668 |
Unlevered Free Cash Flow | 546.59 | 994.56 | 1,400 | 1,557 | 2,580 | 5,847 |
Change in Working Capital | 215.24 | 215.24 | 709.88 | 535.21 | 1,281 | 45.66 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.